Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of efanesoctocog alfa prophylaxis in severe hemophilia A
2019-002023-15Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efanesoctocog alfa in hemophilia A, sponsored by Sanofi. Primary endpoint: Primary efficacy endpoint. Started Oct 2019; status: completed.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2019-002023-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002023-15.